Eli Lilly to present COAST-V, COAST-W data at ACR/ARHP
Eli Lilly announced that it will present new data for Taltz and Olumiant at the American College of Rheumatology, or ACR/Association of Rheumatology Health Professionals, or ARHP, annual meeting. Lilly will present 21 abstracts featuring new data for Taltz, including a late-breaking abstract and four oral presentations. Highlights include complete results from two Phase 3 studies, COAST-V and COAST-W, in adult patients with Ankylosing Spondylitis, or AS, also known as radiographic axial spondyloarthritis, or axSpA. Based on the positive results from the COAST-V and COAST-W studies, the company plans to submit for U.S. regulatory approval in AS/axSpA later this year. In addition, Lilly will highlight new data for Olumiant in 20 abstracts, including seven oral presentations on rheumatoid arthritis, or RA, and systemic lupus erythematosus, or SLE. Notable presentations include an updated integrated safety analysis of Olumiant in the treatment of adults with moderately-to-severely active RA. The FDA approved the 2-mg dose of Olumiant for the treatment of adults with moderately-to-severely active RA who have had an inadequate response to one or more tumor necrosis factor inhibitor therapies in June.